Evidence map›Paper›PMID 22772378›Full record

ArticleJournal of the Royal Society, Interface2012

Vaccine allocation in a declining epidemic.

E Goldstein, J Wallinga, M Lipsitch

Abstract readHistorical Article
In one paragraph

Article in Journal of the Royal Society, Interface, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Multi-period vaccine allocation model in a pandemic: A case study of COVID-19 in Australia.Transportation research. Part E, Logistics and transportation review · 2022
    Article
  2. Dose-Optimal Vaccine Allocation over Multiple Populations.Production and operations management · 2018
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

E GoldsteinCenter for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA. egoldste@hsph.harvard.edu
J Wallinga
M Lipsitch

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI COHEN, THEODORE H · 2009 to 2018
$26.4M
Epidemiology and modeling of the population dynamics of influenza and antimicrobiK01AI101010 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI GOLDSTEIN, EDWARD · 2012 to 2014
$379k
NIAID NIH HHS K01 AI101010NIGMS NIH HHS 1 U54 GM088558NIGMS NIH HHS U54 GM088558
6 · The paper itself

Abstract

Sizeable quantities of 2009 pandemic influenza A/H1N1 (H1N1pdm) vaccine in the USA became available at the end of 2009 when the autumn wave of the epidemic was declining. At that point, risk factors for H1N1-related mortality for some of the high-risk groups, particularly adults with underlying health conditions, could be estimated. Although those high-risk groups are natural candidates for being in the top priority tier for vaccine allocation, another candidate group is school-aged children through their role as vectors for transmission affecting the whole community. In this paper, we investigate the question of prioritization for vaccine allocation in a declining epidemic between two groups-a group with a high risk of mortality versus a 'core' group with a relatively low risk of mortality but fuelling transmission in the community. We show that epidemic data can be used, under certain assumptions on future decline, seasonality and vaccine efficacy in different population groups, to give a criterion when initial prioritization of a population group with a sufficiently high risk of epidemic-associated mortality is advisable over the policy of prioritizing the core group.

Indexed as

Disease OutbreaksHealth Care RationingHistory, 21st CenturyHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesModels, TheoreticalRisk AssessmentSeasonsUnited StatesInfluenza Vaccines

Identifiers

PMID22772378
PMCPMC3479926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.